Lantheus Holdings (LNTH) is back in focus after its investigational PET/CT agent LNTH-2513 (18F-GP1) earned SNMMI’s Image of the Year, tied to clinical data in acute lower-extremity deep vein thrombosis.

The award news comes as Lantheus shares trade at US$100.98, with a 30 day share price return of 8.51% and a 90 day share price return of 26.21%. The 5 year total shareholder return is very large, suggesting momentum has been building over both shorter and longer horizons.

If this kind of radiopharma story has your attention, it may be a good time to see what else is emerging in healthcare focused AI imaging and diagnostics through our 39 healthcare AI stocks

With the stock up strongly over the past year and trading only about 4% below the average analyst price target, the key question now is whether Lantheus still offers upside or if the market is already pricing in future growth.

Most Popular Narrative: 3% Undervalued

With Lantheus trading at $100.98 against a narrative fair value of $104.08, the current story hinges on how radiodiagnostic growth and margins play out under a 7.7% discount rate.

Multiple new product launches within the next 18 months, including the new F-18 PSMA PET, MK-6240, OCTEVY, and PNT2003, are set to diversify the revenue base, mitigate concentration risk, and open additional growth channels in oncology and neuroendocrine tumor imaging, supporting both top-line and future earnings expansion.

Want to see what kind of revenue mix and profit profile that pipeline could support, and which future earnings multiple underpins that fair value math? The full narrative lays out those assumptions in detail, including how fast earnings might compound and what margin structure is baked into that $104.08 figure.

Result: Fair Value of $104.08 (UNDERVALUED)

However, the story can change quickly if PYLARIFY pricing pressure deepens or if new radiopharmaceutical launches deliver less earnings contribution than analysts currently build into their models.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If the mix of optimism and concern in this story feels familiar, it is because investors are weighing both sides in real time, so check the key 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Lantheus has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused screens that surface very different kinds of opportunities.

• Target potential mispricing by scanning companies that combine quality with attractive valuations through the 49 high quality undervalued stocks
• Build steadier income potential by focusing on businesses with higher yields and resilience using the 9 dividend fortresses
• Prioritise capital protection by filtering for companies with stronger balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (46 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.